ClinicalTrials.gg
CompletedNCT04278248Updated Feb 20, 2020

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

A Phase 3 interventional study of 23-Valent Pneumococcal Polysaccharide Vaccine in Pneumonia, Pneumococcal, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jan 2018, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,940
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.

02

Conditions studied

  • Pneumonia, Pneumococcal
03

In context

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's enrollment of 1,940 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2 years old and above healthy people.
  • Subject or legal representative who consent and has signed written .
  • Subject or legal representative who is able to comply with all study procedures.
  • Subject who didn't vaccinate pneumococcal vaccines and did't immune with any within 14 days and inactivated vaccine within 7 days before vaccination.
  • Axillary temperature ≤37.0 ℃.

Exclusion criteria

Exclusion Criteria:

  • History of allergy,eclampsia, epilepsy, encephalopathy and mental disease or family disease.
  • Allergic history after vaccination.
  • Known allergy to any component of the test vaccine(the test vaccine mainly contains 23 types of pneumococcal polysaccharide and PBS buffer)
  • Subjects who diagnosis of thrombocytopenia or other history of coagulopathy.
  • Known immunological impairment or dysfunction.
  • Subjects who have received whole blood, plasma, and immunoglobulin therapy within one month.
  • Known severe congenital malformations, developmental disorders; clinically diagnosed serious chronic diseases: down's syndrome, diabetes, sickle cell anemia or neurological disorders, Guillain Barre syndrome.
  • Known or suspected to suffer from: respiratory system disease,acute infection or chronic disease active period,severe cardiovascular disease, liver and kidney disease, malignant tumor, skin disease,children's mother has infection and other serious and infectious diseases.
  • In pregnancy or lactation or pregnant women.
  • Subjects aged 18 years and above whose systolic blood pressure≥160mmHg and diastolic blood pressure≥100mmHg.
  • Any that investigators consider related to vaccination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,940 participants (actual)

Study arms

  • Experimental
    experimental group

    Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose

    Biological: 23-Valent Pneumococcal Polysaccharide Vaccine

  • Active comparator
    Positive control group

    Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose

    Biological: 23-Valent Pneumococcal Polysaccharide Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity study endpoint

    Percentage of participants with seroresponse to each vaccination

    Time frame: 30 day after each vaccination

  2. Safety study endpoint

    Occurrence of adverse events during a 30 day follow-up period after each vaccination

    Time frame: 30 day after each vaccination

07

Study locations

1 site
  • Yizhou Center for Disease Control and Prevention
    Yizhou, Guangxi 530028, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jun 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Feb 20, 2020
StartActual
Jan 12, 2018
Primary completionActual
Jun 7, 2018
CompletionActual
Jun 7, 2018
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04278248
Responsible party
Sponsor
First posted
Feb 20, 2020
Start date
Jan 12, 2018
Primary completion
Jun 7, 2018
Completion
Jun 7, 2018
Last update
Feb 20, 2020

Study contacts

Du Lin, Master
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion